TaiRx, Inc. (TPEX:6580)

Market Cap	2.67B
Revenue (ttm)	5.32M
Net Income (ttm)	-183.76M
Shares Out	110.58M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,065
Average Volume	119,161
Open	24.10
Previous Close	24.10
Day's Range	23.20 - 24.20
52-Week Range	17.40 - 44.00
Beta	0.55
RSI	47.06
Earnings Date	Aug 8, 2025

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2023, TaiRx's revenue was 5.08 million, a decrease of -26.59% compared to the previous year's 6.92 million. Losses were -212.29 million, 0.34% more than in 2022.